Search Results 971-980 of 13928 for Assay

1. Safety and Efficacy of Polymyxin B Hemoperfusion (PMX) for Endotoxemic Septic Shock in a Randomized, Open-Label Study - Mayo Clinic

   Endotoxin Activity Assay between ≥ 0.60 to <0.90 EA units. 7. Evidence of at least 1 of the following criteria for new onset organ dysfunction that is ...

2. Publications - Erik C. Thorland, Ph.D. - Mayo Clinic

   Clinical performance of the CytoScan Dx Assay in diagnosing ... A multiplex assay for the detection and mapping of complex glycerol kinase deficiency.

3. Precision medicine for breast cancer - Doctors & Departments - Mayo Clinic

   Classification of BRCA2 variants of uncertain significance (VUS) using an ACMG/AMP model incorporating a homology-directed repair (HDR) functional assay.

4. A Study To Assess The Tolerability Of Ianalumab (VAY736) With Investigator's Choice Thrombopoietin Receptor Agonist (IC TPO-RA) In Patients With Primary Immune Thrombocytopenia (ITP) - Mayo Clinic

   Known history of primary or secondary immunodeficiency, or a positive human immunodeficiency virus (HIV) enzyme-linked immunosorbent assay (ELISA) and Western ...

5. A Study Using VE303 to Prevent Recurrence of Clostridium Difficile Infection - Mayo Clinic

   difficile stool assay by EIA for Toxin A and/or B performed at the local laboratory or a study specific assay performed at the central laboratory. Women of ...

6. Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML - Mayo Clinic

   * Participants with newly diagnosed AML with FLT3-ITD mutations (FLT3-ITD \[+\]) present at ≥5% VAF (or ≥0.05 SR) based on a validated FLT3 mutation assay.

7. A Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of Isatuximab in Patients With Multiple Myeloma - Mayo Clinic

   About this study. Primary Objective: - Part A: To evaluate the safety of SAR650984 (isatuximab) in patients with relapsed/refractory multiple myeloma (RRMM) ...

8. A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer - Mayo Clinic

   Biopsy evaluable for expression of PD-L1 as determined by a PD-L1 Immunohistochemistry (IHC) pharma diagnostic test (pharmDx) assay performed by a central ...

9. Safusidenib Phase 2 Study In IDH1 Mutant Glioma - Mayo Clinic

   explorative studies. 4. The IDH mutation, and other applicable gene/molecular alterations (see Table 10-2) are determined by a validated assay as performed in ...

10. Breast cancer - Doctors and departments - Mayo Clinic

    Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.